Project Grant DP2NS155224
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $1.854 million on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research into compartmentalized reactive oxygen species (ROS) sensing in the brain, specifically investigating how neurons balance mitochondrial energy production with ROS control....
- The National Institute of General Medical Sciences awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $443,090 under the Biomedical Research and Research Training program (CFDA 93.859) on September 1, 2026. The award funds a five-year research program investigating the mechanisms of perioperative neurocognitive disorder, a neurotoxic condition arising from anesthesia and surgery that is characterized by declines in memory, attention, and executive...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $322,382 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research investigating cell-specific interleukin-1 receptor 1 (IL-1R1) signaling in focal and diffuse traumatic brain injury models. The research uses genetically engineered mice with precise...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $616,126 on August 26, 2026, to conduct in vivo genome editing research for cerebrovascular disorders under NINDS Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award funds research defining how and when gene editing can restore cerebrovascular and white matter integrity in an ACTA2 R179H...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (Massachusetts General Hospital) $435,550 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853, Assistance Listing). The award funds investigator-initiated research examining the role of DNA methyltransferase 3 alpha (DNMT3A) in oligodendrogenesis and white matter repair following ischemic stroke. The project tests the...
- The National Institute of General Medical Sciences, a component of the Department of Health and Human Services National Institutes of Health, awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $393,689 in project grant funding on August 10, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The award funds research defining mechanisms that couple nutrient sensing to functional programs in non-malignant mammalian cells. The...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded $614,689 to The General Hospital Corporation (doing business as Massachusetts General Hospital) on August 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop patient-based disease-modifying therapeutic strategies for Huntington's disease by targeting FAN1, an...
- This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,173,794 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on enhancing brain resilience to Alzheimer's disease by targeting adult hippocampal neurogenesis. The project aims to explore the mechanisms by which adult hippocampal neurogenesis cooperates with brain-derived neurotrophic factor (BDNF) to potentially slow cognitive decline in...
- The National Institute on Aging awarded The General Hospital Corporation (Massachusetts General Hospital) $660,000 on March 15, 2026, under the Aging Research program (CFDA 93.866) to develop deep learning–based image registration and morphometric analysis tools for structural MRI-derived biomarkers in Alzheimer's disease diagnosis. The project aims to improve the sensitivity and accessibility of longitudinal morphometric metrics derived from T1-weighted structural brain MRI scans—a non-invasive...
- The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
The National Institutes of Health Office of the Director awarded The General Hospital Corporation (Massachusetts General Hospital) $783,750 under the Trans-NIH Research Support program (CFDA 93.310) on September 1, 2026, to conduct therapeutic discovery in neurodegeneration using bioengineered organoids and artificial intelligence-driven genomics approaches. The award funds development of multiplexed differentiation strategies to generate midbrain organoids that integrate all major brain cell types, enabling investigation of non-cell-autonomous mechanisms in neurodegeneration. The recipient will conduct functional genomics screens mapping genotype-to-phenotype relationships in multicellular contexts, generate large datasets for deep learning analysis, and integrate those datasets with human and preclinical data to develop an in silico model of neurodegeneration. Computational predictions of therapeutic targets will be evaluated iteratively in midbrain organoids using active learning methodology to refine predictions and optimize therapeutic interventions. Work is performed in Boston, Massachusetts. The period of performance runs through June 30, 2031. The assistance type is Project Grant, subject to the peer review and audit requirements of OMB 2 CFR 200 as implemented through 45 CFR 75.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $783.8k | 8/28/26 |